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Abstract The prevalence of pregnant women with cardiovas-
cular heart disease is increasing. Transthoracic echocardiogra-
phy is safe during pregnancy, and it is an important diagnostic
tool in pregnant women with established heart disease in order
to monitor ventricular and valvular anatomy and function. In
addition, it can be used to delineate cardiac anatomy in com-
plex congenital heart disease and help stratify maternal risk
during pregnancy. This review will focus on the use of echo-
cardiography in the diagnosis and management of pregnant
women with common congenital lesions and with prosthetic
valves.
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Introduction
Cardiovascular disease is a common cause of maternal mor-
tality. Maternal risk during pregnancy can be assessed accord-
ing to the modified World Health Organization (WHO) risk
classification. In women who are WHO class I and II, risk is
considered to be low to moderate and WHO Class III is
considered high risk. In women who are WHOClass IV, preg-
nancy is considered a contraindication [1]. Transthoracic
echocardiography is a safe and an important diagnostic tool
in pregnant women with established heart disease in order to
monitor cardiac condition and valvular function [2••].
Transesophageal echocardiography, although rarely required,
is relatively safe during pregnancy and is particularly useful to
delineate cardiac anatomy in patients with complex congenital
heart disease. This review will focus on common congenital
lesions and prosthetic valve disease and the advantages of
echocardiography in the diagnosis and management of preg-
nant women.
Echocardiography in Pregnant Women
with Congenital Heart Disease
Due to advances in surgical repair, the number of women with
congenital heart disease (CHD) who survive to childbearing
age is increasing [3]. The main pathophysiologic mechanisms
in pregnant women with CHD include volume overload, left-
to-right shunts, pressure overload, and cyanotic right-to-left
shunts [4]. Table 1 summarizes a list of CHD with increasing
maternal risk. In general, pregnant women are able to tolerate
left-to-right shunts without complications—which is not gen-
erally true for right-to-left shunts. For example, maternal mor-
tality is similar to the general population with atrial septal
defects compared to Eisenmenger’s syndrome, which carries
an estimated risk between 25 and 50 % [5–7]. Regardless of
pregnancy, echo interpretation is best achieved by a systemat-
ic interrogation of the atrial, ventricular, and great arterial seg-
ments, with determination of atrial and ventricular situs and
connections of the atria to the ventricles and of the ventricles
to the great arteries [8].
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Specific Congenital Heart Defects
Atrial Septal Defect
Many women with atrial septal defects (ASD) may remain
asymptomatic and are diagnosed initially during pregnancy.
ASDs are generally associated with a left-to-right shunt across
the septum. Shunt size can be estimated by 2D echo and pulse
wave (PW) Doppler velocity measurements to estimate flow
volume across the pulmonary and systemic circulations
(expressed by the Qp/Qs ratio). Flow volume is the product
of time velocity integral of blood flow and the cross-sectional
area of the outflow tract. The degree of shunting depends on
the defect size and right ventricular compliance. Usually, a
typical ostium secundum ASD is well tolerated if there is no
significant shunting [9]. Closure of a hemodynamically sig-
nificant ASD should be performed before pregnancy due to
risk of arrhythmia and thromboembolic complications [9, 10].
During pregnancy, increases in cardiac output and blood vol-
ume are counterbalanced by a decrease in pulmonary vascular
resistance, with a resultant decrease in left-to-right shunting
[11]. Echocardiography is useful in determining defect size,
right atrial enlargement, right ventricular volume overload,
and quantification of shunt size. Most importantly, pulmonary
artery pressure can be estimated, which is a key determinant of
maternal outcome (Fig. 1). In addition, contrast echocardiog-
raphy for detection of significant shunting is not needed due to
assessment by color Doppler and other features of a larger
ASD or VSD. In general, saline contrast should be avoided
during pregnancy to minimize any possible embolic risk [12].
Closure of an ASD is not indicated unless the mother is dete-
riorating; however, it can be performed during pregnancy if
needed using transesophageal or intracardiac echo guidance
[4].
Ventricular Septal Defect
In contrast to ASDs, ventricular septal defects (VSD) are typ-
ically diagnosed and treated in childhood. Most detected
VSDs in adulthood are small, perimembranous, and restric-
tive, with normal pulmonary artery pressure. On Doppler, a
high velocity jet is seen from LV to RV with normal chamber
dimensions and function [12]. These defects are well tolerated
during pregnancy [4, 13]. However, in the presence of a large
defect, left ventricular volume overload and RV hypertrophy
occur. If pulmonary hypertension is present, shunt reversal can
occur if there is significant reduction of the systemic blood
pressure. In this case, serial echocardiography should be per-
formed to evaluate for ventricular dysfunction and progres-
sion of pulmonary hypertension [11]. For patients with a his-
tory of corrected VSD, echocardiography should be per-
formed prior to pregnancy to exclude presence of any residual
VSD, to assess ventricular function and pulmonary artery sys-
tolic pressure (PASP). For patients with a prior history of
primum ASD, echocardiography should be performed pre-
pregnancy to evaluate for the presence of residual shunt, atrio-
ventricular valve (AV) regurgitation, ventricular function, and
PASP. Those with a significant shunt or with symptoms and
with significant AV valve regurgitation should undergo cor-
rective surgery prior to pregnancy provided pulmonary vascu-
lar resistance is normal [14].
Table 1 Modified WHO classification of maternal cardiovascular risk
in congenital heart disease
Low risk (WHO I)
Mild pulmonary stenosis
Small patent ductus arteriosus
Mitral valve prolapse with <mild mitral regurgitation
Successfully repaired atrial or ventricular septal defect, patent ductus
arteriosus, anomalous pulmonary venous drainage
Intermediate risk (WHO II or III)
WHO II (if otherwise well and uncomplicated)
Unoperated atrial or ventricular septal defect
Repaired tetralogy of Fallot
WHO II–III (depending on individual)
Mild left ventricular impairment
Hypertrophic cardiomyopathy
Native or tissue valvular heart disease not considered WHO I or IV
Marfan Syndrome without aortic dilatation
Aorta <45mm in aortic disease associated with bicuspid aortic valve
Repaired coarctation




Cyanotic heart disease (unrepaired)
Other complex congenital heart disease
Aortic dilatation 40–45 mm in Marfan syndrome
Aortic dilatation 45–50 mm in aortic disease associated with bicuspid
aortic valve
Very high risk (WHO IV-pregnancy contraindicated)
Eisenmenger’s Syndrome Table
Marfan syndrome with aorta dilated >45 mm
Aortic dilatation >50 mm in aortic disease associated with bicuspid
aortic valve
Native severe aortic coarctation
Severe systolic ventricular dysfunction (LVEF<30 %)
Previous peripartum cardiomyopathy with residual LV systolic
dysfunction
Severe mitral stenosis
Severe aortic stenosis (with symptoms)
Modified from Thorne et al. [1], with permission from BMJ Publishing
Group Ltd., and modified from Regitz-Zagrosek et al. [2••], with permis-
sion from Oxford University Press
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Patent Ductus Arteriosus
Similar to VSDs, left ventricular overload and pulmonary hy-
pertension can be detected in pregnant women with a large
patent ductus arteriosus (PDA). In a small PDA, chamber
sizes are usually normal, although mild left atrial and left
ventricular enlargement may be present. Careful color and
spectral Doppler evaluation should be performed (in the
parasternal and supasternal views). In significant PDA, main
and branch pulmonary arteries are dilated, color aliasing is
seen in systole and diastole in the main and branch pulmonary
arteries depending on the location of PDA communication,
and CW Doppler shows continuously increased systolic and
diastolic velocities across the pulmonary arteries. Further
evaluation should be performed in the suprasternal view to
visualize the main pulmonary artery and right pulmonary ar-
tery, as well as the proximal descending aorta to visualize the
PDA. If during pregnancy, left atrial and ventricular enlarge-
ments are more than expected and diastolic flow reversal is
seen in the descending aorta in the absence of severe aortic
regurgitation, a PDA should be suspected [12].
Pulmonary Hypertension and Eisenmenger’s
Syndrome
Pulmonary hypertension encompasses multiple condi-
tions, including pulmonary arterial hypertension (idio-
pathic or heritable), pulmonary hypertension related to left
heart disease, pulmonary hypertension related to lung dis-
ease and/or hypoxia, chronic thromboembolic disease,
and pulmonary hypertension associated with congenital
heart disease, with or without previous corrective surgery.
A PASP of 50 mm Hg or greater than two-thirds the sys-
temic pressure is considered high-risk during pregnancy.
A high maternal mortality risk is reported (20–50 % in
older series and 17–33 % in more recent papers) in pa-
tients with severe pulmonary arterial hypertension and
Eisenmenger’s syndrome [6]. In Eisenmenger’s syndrome,
the pulmonary vascular resistance is equal or higher than
in the systemic circulation. Pulmonary hypertensive crisis
and right heart failure are often the cause of maternal
mortality in the peri-partum or postpartum period [15].
Even with the advancement of both obstetric and
Fig. 1 Incidental secundum atrial septal defect (ASD) measuring
1.9 × 1.5 cm seen in a pregnant patient who decompensated during
delivery (a). Echo-Doppler revealed bidirectional shunting (b) and
severely elevated peak right ventricular systolic pressure (RSVP),
greater than 55 mm Hg (c). Patient was treated with intravenous
diuretics and vasodilators. RVSP improved and patient was discharged
home
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anesthetic managements, the maternal mortality still ex-
ceeds 25 % and significant functional deterioration occurs
in the remaining patients [16]. Eighty percent of deaths
occur between the 2nd and 30th postnatal day [17].
Once conception occurs in patients with Eisenmenger’s
syndrome and severe pulmonary hypertension, interrup-
tion of pregnancy is still the best manipulation to be rec-
ommended. The primary anesthetic goal is to avoid any
hemodynamic change that might increase the right-to-left
shunt and thereby increase hypoxemia [18]. Treatment
with sildenafil and L-arginine [19] or epoprostenol [20]
has been reported to improve maternal and fetal outcome
in isolated case reports. In addition, when HELLP syn-
drome (hemolysis, elevated liver enzymes, and low plate-
let count) occurs, more commonly seen in eclampsia and
pre-eclampsia, it may cause an unfavorable outcome. The
morbidity and mortality rates associated with HELLP syn-
drome have been reported to be as high as 25 % [21].
PASP may be difficult to detect in these patients due to
an inadequate tricuspid regurgitant jet. Therefore, the
presence of pulmonary hypertension can be inferred from
evidence of a large, nonrestrictive cardiac communication,
a short time-to-peak velocity on pulsed wave Doppler of
the pulmonary artery, midsystolic notching of the pulmo-
nary valve on M-mode echo, and abnormal ventricular
septal motion. Increases of volume during pregnancy are
poorly tolerated by the right ventricle, and the fall in sys-
temic vascular resistance increases right-to-left shunting
worsening cyanosis. Eisenmenger’s syndrome is associat-
ed with a high maternal risk (WHO Class IV) and high
fetal risk, with high rates of spontaneous abortion and
intrauterine growth retardation [2••]. Figures 2 and 3 are
transthoracic echocardiographic and TEE images respec-
tively in a 20-year-old Hispanic G1P0 who was transferred
at 27-week gestation with a diagnosis of severe primary
pulmonary hypertension. There was evidence of polycy-
themia (Hgb 16 g, Hct 48 %), finger clubbing, central
cyanosis, right axis deviation, and RV hypertrophy on
ECG. There was severe pulmonic insufficiency and
PASP was 90 mm Hg. A PDA was diagnosed based on
a saline contrast study that showed appearance of bubbles
in the proximal thoracic aorta and aortic arch and not in
the left ventricle. PASP reduced to 80 mm Hg on inhaled
nitric oxide treatment. Due to fetal distress and maternal
hypoxemia, a semi-emergent cesarean section was per-
formed at 28-week gestation and a live female fetus was
delivered. On postoperative day 2, patient underwent re-
exploration of abdomen due to marked hypotension and
marked cyanosis (reversal of shunt from PDA to aorta due
to hypotension), and large amounts of clot were removed
from the abdomen. Subsequently, the patient developed
thrombocytopenia, disseminated intravascular coagula-
tion, and elevated liver enzymes and died within 24 h.
Pulmonic Stenosis
Many patients with pulmonic stenosis remain asymptomatic
throughout early adulthood. Mild-to-moderate pulmonic ste-
nosis is generally tolerated well during pregnancy. Severe pul-
monic stenosis (peak Doppler gradient >64 mm Hg) can lead
to right heart failure and arrhythmia and should be corrected
before pregnancy [22–24]. However, secondary to the RV
hypertrophy that occurs, women may be sensitive to the vol-
ume overload that occurs during pregnancy. A patent foramen
ovale may be associated with PS, and in the setting of severe
PS, there may be increased right-to-left shunting at the level of
the atria [24].
Left Ventricular Outflow Obstruction
This may be valvular, subvalvular (discrete membrane), or
supravulvular. Congenital aortic stenosis (AS) is most com-
monly caused by a bicuspid aortic valve. Obstruction to aortic
outflow results in LV hypertrophy and preload dependence,
which may be problematic during labor, where significant
volume shifts occur. Women with moderate or severe aortic
stenosis with NHYA Class II symptoms are at risk for devel-
oping heart failure and premature labor. Echocardiography is
useful in the assessment of LV function, aortic valve
area, and transvalvular Doppler pressure gradients.
Speckle tracking ultrasound can be used to assess lon-
gitudinal strain and LV twist. In a small study, LV twist
in women with AS significantly increased during preg-
nancy compared to nonpregnant women [25]. Bicuspid
aortic valves are associated with aortopathy and a
higher risk of dissection. Women with bicuspid aortic
valves should have their aortic root and ascending aorta eval-
uated by echocardiography before pregnancy. It is usually
recommended that patients with bicuspid aortic valves and
aortic root dilation >4.5 cm should avoid pregnancy [22].
Coarctation of Aorta
Echocardiography should be performed in patients with a his-
tory of coarctation repair to evaluate for recurrence of coarc-
tation and residual gradient and aortic aneurysm, as well as for
the presence of a bicuspid aortic valve. Unrepaired coarctation
of the aorta in pregnancy can cause increased risk of maternal
hypertension and intrauterine growth retardation. Obtaining
2D scans of the coarctation may be difficult, but if a coarcta-
tion is seen will reveal a focal narrowing of the thoracic aorta
distal to the left subclavian artery and turbulent flow on color
Doppler. CW Doppler shows a high systolic velocity with a
continued gradient in diastole. Due to the aortopathy risk as-
sociated with coarctation, there is an increased risk of aortic
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dissection during pregnancy. Additionally, aneurysm in the
area of prior surgical repair can be seen in patients with coarc-
tation. Both transthoracic and transesophageal echocardiogra-
phy can be used to detect re-coarctation and evaluate pressure
gradients across the thoracic aorta, or aneurysm complica-
tions. These patients represent a higher risk group and consid-
eration of aneurysm repair before pregnancy may be warrant-
ed. In some cases, echocardiographic evaluation may be in-
sufficient for full evaluation of aortic aneurysms, and other
imaging modalities, such as magnetic resonance imaging or
computed tomography, may be needed [26].
Marfan’s Syndrome
Similar to bicuspid aortic valve and coarctation of the aorta,
Marfan’s syndrome is associated with aortopathy.
Women with Marfan’s syndrome in whom cardiovascu-
lar involvement is minor and the aortic root diameter is
<40 mm tolerate pregnancy well. Conversely, patients
with significant aortic dilation may experience more
complications. In these patients, echocardiography should be
done at 6–8-week intervals throughout the pregnancy until
6 months postpartum [27].
Fig. 3 Due to fetal distress and maternal hypoxemia, a semi-emergent
cesarean section was performed and a 28-week live female fetus was
delivered. Intraoperative transesophageal echocardiographic images
showing a large (1.8 cm in diameter) patent ductus arteriosus (double
white asterisks) connecting with proximal thoracic aorta (Ao) (a). b
shows aortic arch (white arrowhead). There was bidirectional flow
across PDA. On postoperative day 2, patient underwent re-exploration
of abdomen due to marked hypotension and marked cyanosis (reversal of
shunt from PDA to aorta due to hypotension), and large amounts of clot
were removed from the abdomen. Subsequently, the patient developed
thrombocytopenia, disseminated intravascular coagulation, and elevated
liver enzymes and died within 24 h
Fig. 2 A 20-year-old Hispanic G1P0 was transferred with a diagnosis of
primary pulmonary hypertension at 27-week gestation. There was
evidence of polycythemia (Hgb 16 g, Hct 48 %), finger clubbing, and
central cyanosis. Pulmonary artery pressure was 90 mm Hg and reduced
to 80 mm Hg with inhaled nitric oxide. a Parasternal long-axis view
showing severe right ventricular enlargement (white line), a small left
ventricular cavity, and paradoxical IVS motion. b RV inflow view
showing marked right ventricular hypertrophy (white arrow). LV left
ventricle, RA right atrium, RV right ventricle
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Ebstein’s Anomaly
Ebstein’s anomaly is a rare condition in which the tricuspid
valve is more apically displaced, causing Batrialization^ of the
right ventricle. A 20 mm or 8 mm/m distance between the
septal tricuspid and anterior mitral leaflet is diagnostic [28].
This causes the right atrium to be large and the morphologic
right ventricle to be small. It is often associated with patent
foramen ovale or ostium secundum ASD defects. Paradoxical
emboli and hypoxemia may occur secondary to reversal of
shunt due to increased right heart pressure. RV failure can
occur secondary to the increase in cardiac output and blood
volume during pregnancy [11]. Echocardiography can be used
to estimate the degree of tricuspid regurgitation and RV func-
tion. Tricuspid regurgitation is usually moderate-to-severe,
and color Doppler can detect multiple jets from fenestrations
of the leaflets [8]. In general, women with Ebstein’s anomaly
without cyanosis and heart failure symptoms tolerate pregnan-
cy well [2••]. In women with severe symptomatic tricuspid
regurgitation or heart failure symptoms, tricuspid valve repair
should be performed before pregnancy.
Tetralogy of Fallot
Tetralogy of Fallot (ToF) is one of the most commonly
repaired congenital lesions seen in adulthood [29–31].
Unoperated ToF is rare in adulthood and is associated with
cyanosis and severe right ventricular hypertrophy. In these
women, pregnancy is not advised because of poor maternal
and fetal outcomes [32]. ToF repair includes relief of RVout-
flow obstruction with incision of the infundibular free wall,
resection of obstructive muscle bundles, disruption of the pul-
monary valve with partial or complete excision (which leads
to pulmonic regurgitation in the majority of patients), and
placement of an outflow patch, which often extends across
the plane of the pulmonary valve into the main pulmonary
artery. In some patients, a conduit between the RV and the
pulmonary arteries is required to provide antegrade pulmo-
nary blood flow. The ventricular septal defect is closed with
a patch, a procedure that can impair tricuspid valve function.
In individuals who have undergone repair, echocardiography
should be performed before conception to evaluate RV size
and RV function—particularly RV outflow tract function, re-
sidual pulmonic valve stenosis, pulmonic regurgitation sever-
ity, and systolic gradient and regurgitation of the pulmonic
valve prosthesis, if present. Pulmonic regurgitation post-ToF
surgery is well tolerated for many years until the third postop-
erative decade but thereafter may result in progressive RV
enlargement and dysfunction. Other residual lesions include
persistent RV outflow tract obstruction, residual VSD, aortic
dilation, and aortic regurgitation. Due to RVenlargement and
paradoxical septal motion or prior cardiopulmonary bypass,
LV dysfunction may also occur [11, 33]. Elective pulmonary
valve replacement is recommended for severe pulmonic re-
gurgitation with RV enlargement [(RV end systolic volume
index >80 ml/m2, end diastolic volume index >150 ml/m2,
and RVejection fraction less than 47% onmagnetic resonance
imaging (MRI)] and exercise intolerance before pregnancy
[2••, 34]. MRI is the gold standard to assess RV volumes
and ejection fraction. Figure 4 shows echo images in a patient
with ToF at 23-week gestation.
Complete (D) Transposition of the Great Arteries
In 90 % of patients with complete D-transposition of the great
arteries (D-CTGA), the aorta is anterior and to the right of the
posterior and leftward pulmonary trunk, which can be identi-
fied on 2D echocardiography. The aorta is identified by the
coronary arteries and the brachiocephalic arteries, while the
pulmonary artery is identified by its major branches [8]. D-
CTGA may be associated with VSD, subpulmonary outflow
obstruction, and coarctation of the aorta. Most adults have un-
dergone repair with an atrial switch (Mustard or Senning) or
arterial switch (Jatene repair). The atrial switch entails a baffle
that redirects systemic venous return to the anatomic LVand the
pu lmona ry venous re tu rn to the ana tomic RV.
Echocardiography can evaluate complications such as baffle
leaks or obstruction, vena caval or pulmonary venous obstruc-
tion, systemic atrioventricular valve (tricuspid) regurgitation,
aortic regurgitation, and left and/or right ventricular dysfunc-
tion [8]. Arterial switch is the preferred surgical approach and
commonly performed now. Complications include RVoutflow
tract obstruction, neoaortic and pulmonary regurgitation and
dilation of the neoaortic root [32]. A comprehensive echocar-
diogram is essential before pregnancy and patients with a
Mustard or Senning repair who should have monthly or bi-
monthly cardiac echocardiograms during pregnancy, to evalu-
ate for development of pulmonary hypertension, severe tricus-
pid regurgitation, and RV dysfunction [2••]. Only a small series
of patients with an arterial switch operation and pregnancy have
been described so far, and the risk is low when the patients are
in good clinical condition prior to conception [2••, 35].
Congenitally Corrected L-Transposition of the Great
Arteries
Congenitally corrected L-transposition of the great arteries (L-
CTGA) is a rare form of CHD, in which there is atrioventric-
ular and ventriculoarterial discordance. In this case, the RV
serves as the systemic ventricle. The morphologic right ven-
tricle is in the subaortic position and can be identified by the
septal insertion of the left atrioventricular valve (tricupsid
valve) that is more apically displaced compared to the right
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atrioventricular valve (mitral valve). The morphologic RV can
also be identified by a moderator band. Associated defects
include VSD, pulmonary stenosis, and Ebstein’s-like anomaly
of the tricuspid valve. Outcomes of pregnancy depend on
associated defects and systemic ventricular function. For both
D- and L-TGA, women with NHYA Class III–IVand ventric-
ular function <40 % and those with severe systemic atrioven-
tricular valve regurgitation should be counseled against preg-
nancy. During pregnancy, evaluation for systemic atrioven-
tricular valve regurgitation and systemic ventricular dysfunc-
tion is critical. Echocardiographic surveillance should be per-
formed every 4 to 8 weeks [2••].
Fontan Circulation
The Fontan operation is a palliative procedure to relieve cya-
nosis by directing systemic venous blood directly to the pul-
monary arteries, in a patient in whom a single ventricle sup-
plies both the systemic and pulmonary circulation. 2D echo
and spectral Doppler assessment are essential in the evaluation
of atriopulmonary or venopulmonary anastomosis and atrio-
ventricular valve regurgitation. Complications which can be
identified include cavoatrial shunting, atrial septal shunting,
and obstruction to the surgically created anastomotic sites.
Due to the increased venous flow in pregnancy and the fixed
cardiac output of a Fontan circulation, women are at high risk
of atrial arrhythmias and right-sided heart failure [11]. TEE
has been recommended to rule out right atrial thrombi due to
sluggish venous Fontan flow [36]. Pregnant women with
Fontan circulation are considered high risk (WHO Class III),
but pregnancy can be achieved safely depending on the phys-
iology of the Fontan circuit [2••, 37, 38].
Prosthetic Valve Disease
Pregnancy outcomes are significantly affected by the presence
of prosthetic heart valves (PHV). Prior to surgery, a detailed
discussion regarding the type of valve needs to be considered.
Fig. 4 Echocardiographic images in a 24-year-old female G1 at
23 weeks with tetralogy of Fallot and surgeries at ages 3, 6, and 9 with
VSD repair, pulmonic valve repair, and then replacement with a
homograft. She also had a permanent pacemaker placement at age 14.
NYHA class was II (able to walk two to three blocks at ground level and
up 10 stairs). Images show the VSD patch in a (white arrow). There was
no residual VSD flow and there was trace aortic regurgitation (b).
Turbulent color Doppler flow across pulmonic prosthesis (c) with peak
and mean gradients of 32 and 25 mm Hg, respectively, is shown (d).
Patient is being closely followed in the OB cardiology clinic. The RV
was mildly enlarged with paradoxical IVS motion and mildly reduced
with RV systolic function. RVoutflow tract was mildly dilated and there
was intrinsic atrial rhythm (86–88 bpm) without RV pacing
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Specifics include durability of valve, thromboembolic risk,
and the use of anticoagulation. Previously, it was reported that
the rate of bioprosthetic valve degeneration in young patients
(ages 16–39) was high, 50 % at 10 years and 90 % at 15 years
[39]. Overall, about 50 % of women of childbearing age will
require valve replacement 10 years after the initial operation
with a bioprosthetic valve, and this risk is greatest when the
bioprosthesis is in the mitral position [40]. There are conflict-
ing data on whether there is an accelerated bioprosthetic valve
degeneration during pregnancy [41–46] or whether there is
just the natural deterioration of tissue valves [47, 48].
Bioprosthetic valves have a low thromboembolic risk, thus
avoiding the need of anticoagulation and decreasing the risk
of bleeding. Conversely, mechanical valves have great
durability, but a higher risk of embolic events (3 to 5 %) and
valve thrombosis (8 to 9 %). Overall, maternal mortality is
higher with mechanical valves (4 to 8 %) compared to
bioprosthetic valves (0 to 5 %) [12]. Despite the type of
prosthesis, echocardiography is critical in identifying
valve dysfunction and for management during pregnancy
(Figs. 5 and 6).
Evaluation of prosthetic valves may be confounded by the
normal hemodynamic changes that occur during pregnancy.
Both the increased heart rate and stroke volume can alter
Doppler evaluation of velocities and pressure gradients across
the prosthetic valves. New murmurs can be secondary to a
physiologic increase in flow; however, at least one echocar-
diogram should be performed during pregnancy and should be
done with any development of symptoms. Similar to imaging
native valves, prosthetic valve assessment includes color flow,
PW and CW Doppler from multiple windows. Particular at-
tention should be paid to occluded leaflet motion, pres-
ence or absence of echo densities attached to the sewing
ring, cage, or struts, and the integrity of the sewing
ring/annular interface [49]. These elements may be dif-
ficult to evaluate with standard 2D techniques because
of shadowing and reverberation artifacts; therefore, 3D
echo and TEE can be advantageous. Multiple off-axis
views are often needed to evaluate valve morphology
and function. Both transthoracic echo and TEE are used
to evaluate for valve thrombosis when a pregnant woman with
a mechanical valve presents with dyspnea and/or embolic
events. Fluoroscopy can be helpful to determine the presence
of prosthetic valve dysfunction but should be used in caution
in pregnant women.
Prosthesis-Patient Mismatch
Elevated transvalvular gradients can be seen secondary to in-
trinsic valve dysfunction but can also be seen in high flow
states such as pregnancy, due to increased heart rate and blood
volume. Therefore, careful evaluation of valve structure and
comparison to prior echocardiograms are helpful to compare
to postoperative (baseline) values. Prosthesis-patient mis-
match (PPM) occurs when a valve is placed that is too small
for a patient’s body size, resulting in a smaller area compared
to the native valve [50]. In general, in patients with PPM, high
gradients are already present in the early postoperative period.
There have only been two case reports of patient prosthesis
mismatch in pregnancy [51, 52]. PPM is defined by an
indexed effective orifice area of <0.85 cm2/m2 for aortic pros-
theses and <1.2 cm2/m2 for mitral prostheses. Severe mis-
match occurs when the indexed effective orifice area is
<0.65 cm2/m2 for aortic prostheses and <0.9 cm2/m2 for mitral
protheses [53]. It is important to distinguish PPM from path-
ologic obstruction (e, thrombus or pannus). With pathologic
obstruction, valve leaflet motion and function will be
abnormal.
Acquired Prosthetic Valve Stenosis
Prosthetic valve stenosis can be secondary to thrombosis, en-
docarditis, pannus formation, or calcific degeneration of the
valve leaflets. On serial echocardiograms, significant in-
creases in gradients will be seen over time. Acceleration time
(AT) can be used to help differentiate between aortic PPM vs
acquired prosthetic stenosis. AT is measured from the onset of
aortic flow to the peak velocity flow. PPM is associated with
an AT <100 ms, compared to pathologic obstruction, in which
AT is >100 ms [54]. The calculation of effective orifice area
for both aortic and mitral valves requires measurement of the
left ventricular outflow tract diameter, which can be challeng-
ing in the presence of an aortic valve prosthesis because of
shadowing. Undermeasurement of LV outflow tract diameter
will result in overestimation of aortic stenosis severity. In this
situation, the Doppler velocity index (DVI) can be helpful. It
is calculated as the ratio of the proximal flow velocity (or
velocity time integral) in the LV outflow tract to the peak
transprosthetic valve flow velocity (or velocity-time integral)
(Fig. 7). For a mitral valve prosthesis, DVI is the ratio of the
transprosthetic valve velocity to the LV outflow tract flow
velocity. A normal DVI for an aortic prosthesis is >0.3 and
for a mitral prosthesis is <2.2. A DVI of <0.25 reflects severe
aortic stenosis [55].
Prosthetic Valve Thrombosis
It is essential to establish if prosthetic valve dysfunction is
secondary to pannus formation versus thrombus to determine
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appropriate treatment. In general, pannus is annular in loca-
tion, gradually progressive, more common in the aortic posi-
tion, and occurs in patients who have been on subtherapeutic
anticoagulation [55]. Comparison to prior gradients and rate
of increase in gradients is important. With valve thrombosis,
increase in gradients and symptoms can be abrupt. In practice,
both pannus and thrombus formation may be present together.
When valve thrombosis is diagnosed, thrombolysis has been
considered to be safe and effective during pregnancy in most
patients; however, complications of bleeding and death have
occurred [40]. Surgery is recommended if anticoagulation
fails, in decompensated patients with obstructive thrombosis
or with a large thrombus (>10 mm) and associated embolism
[56]. However, surgery during pregnancy is associated with
both increased maternal and fetal morbidity (24 and 9 %, re-
spectively) and mortality (6 and 30 %, respectively) [57].
Ozkan demonstrated that TEE-guided, low-dose, slow infu-
sion (6 h) of tissue-type plasminogen activator (tPA) was a
safe and effective strategy for the treatment of prosthetic valve
thrombosis in a small observational study. Both transthoracic
echo and TEE were done prior to and 1 h postinfusion to
assess for efficacy. After thrombolysis, mean valve area, peak,
and mean gradients improved significantly, with no remaining
visualized thrombus [56].
Fig. 5 Thirty-two-year-old female with prior successful C-section
4 years ago developed hypotension postelective C-section at 37-week
gestation. She had undergone bioprosthetic aortic valve replacement
with a Carpentier-Edwards pericardial valve for severe aortic stenosis in
a bicuspid aortic valve and aortic root enlargement with a pericardial
patch due to a small aortic root 5 years ago. Due to dyspnea and an
increase in mean prosthetic aortic valve gradient from 19 mm Hg pre-
pregnancy to 51 mm Hg at 21-week gestation, an elective C-section was
performed at 37 weeks. After extubation post-C-section, she developed
pulmonary edema with a pulmonary capillary wedge pressure of 28 mm
Hg and required pressor support. Transesophageal echocardiographic
images showing calcified bioprosthetic aortic valve leaflets with
restricted motion (thick white arrow) and prior pericardial patch (thin
white arrows) in a and severely increased aortic valve gradient at
121 mm Hg in b
Fig. 6 Transesophageal echocardiographic color Doppler images in the
same patient as in Fig. 5 showing systolic Doppler flow convergence
(PISA) toward the aortic valve at a normal aliasing velocity indicating a
markedly increased gradient at the valve level from severe aortic stenosis
in a and diastolic flow convergence (PISA) above the aortic valve at a
normal aliasing velocity indicating severe aortic regurgitation in b. An
emergent surgery was performed. Aortic leaflets were found fixed in mid
open position. She underwent aortic valve replacement with a St. Jude
Regent valve
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Prosthetic Valve Regurgitation
Bioprosthetic valve regurgitation is secondary to leaflet de-
generation. Mechanical valve prostheses are commonly de-
signed with a bileaflet occluding mechanism. These valves
have two small Bwashing jets^ traveling between the inner
edge of the sewing ring and the outer edge of the leaflets. In
theory, these jets help to prevent thrombus formation.
Pathologic transvalvular regurgitation is generally caused by
thrombus or pannus formation causing incomplete closure of
the discs—as opposed to paravaluvlar regurgitation, which is
secondary to dehiscence of the valve ring. Quantification of
regurgitation is similar to the assessment in native valves,
except mechanical mitral prostheses that have significant
shadowing, making color Doppler interpretation more diffi-
cult. If regurgitant jets are reliably visualized, then the stan-
dard methods for native valve assessment can be used to esti-
mate the degree of severity. If transthoracic imaging is unsuc-
cessful, TEE imaging may be indicated. Several parameters,
such as mitral E velocity and Doppler velocity index, have
been used to predict mitral regurgitation but have not been
validated [49].
Conclusion
The prevalence of pregnant women with cardiovascular heart
disease is increasing. Echocardiographic assessment of
biventricular function, valve function, quantification of
shunts, and pulmonary pressure is essential. For mechanical
and bioprosthetic valves, quantification of the degree of ste-
nosis and regurgitation is similar to native valve assessment;
however, gradients and the type of normal regurgitant jets
vary depending on the type of valve. Echocardiography can
be used for preconception counseling, to help advise termina-
tion of pregnancy in high-risk conditions and to decide mode
of delivery. Lastly, both transthoracic echo and TEE have been
used tomonitor diagnostic and therapeutic procedures, such as
treatment in valve thrombosis, percutaneous ASD closures,
and balloon mitral valvotomy [12, 56, 58].
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Fig. 7 A 31-year-old pregnant woman with a history of St. Jude 21-mm
bioprosthetic aortic valve replacement in 6 years ago (a, short-axis view)
was found to have elevated gradients across her aortic valve on routine
echocardiogram during her first trimester with an aortic valve area of
0.75 cm2 by continuity equation indicating severe aortic stenosis.
Doppler velocity index—a ratio of PW Doppler subvalvular velocity
(b) and the maximum CW Doppler velocity across aortic valve (c) was
0.25 indicating nonsevere aortic stenosis. Patient was followed closely
throughout pregnancy and had normal vaginal delivery without any
complication
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